Based on the latest data from Oct 13, 2026, ACAD's PEG ratio sits at 0.12. This metric combines a PE of 8.28 with an earnings growth rate of 67.9%. Relative to the 0.16 average from the past 4 quarters, the PEG ratio fell by 24%.
Looking at the past three years, ACAD's PEG ratio has settled around 0.17 on average. At 0.12, today's PEG ratio sits 29% lower than its historical average. Within the past three years, the Jun 2024 quarter saw the highest PEG reading at 0.72. At 0, the Mar 2025 quarter represented the lowest PEG ratio in this timeframe.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.17 | 11.51 | 69.3% |
| 2024 | 0.03 | 13.39 | 470.3% |
| 2023 | N/A | N/A | 72.4% |
| 2022 | N/A | N/A | -27.6% |
| 2021 | N/A | N/A | 41.3% |
| 2020 | N/A | N/A | -11.9% |
| 2019 | N/A | N/A | 17.5% |
| 2018 | N/A | N/A | 17.8% |
| 2017 | N/A | N/A | -0.9% |
| 2016 | N/A | N/A | -43.6% |
| 2015 | N/A | N/A | -71.6% |
| 2014 | N/A | N/A | -115.9% |
| 2013 | N/A | N/A | -15.8% |
| 2012 | N/A | N/A | 13.6% |
| 2011 | N/A | N/A | -212.8% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.17 | 11.24 | 67.9% |
| Mar 2026 | 0.16 | 9.98 | 61.6% |
| Dec 2025 | 0.17 | 11.51 | 69.3% |
| Sep 2025 | 0.13 | 13.59 | 101.3% |
| Jun 2025 | 0.02 | 16.1 | 644.4% |
| Mar 2025 | 0 | 12.04 | 13,900% |
| Dec 2024 | 0.03 | 13.39 | 470.3% |
| Sep 2024 | 0.11 | 19.72 | 184.8% |
| Jun 2024 | 0.72 | 90.28 | 126.1% |
| Mar 2024 | N/A | N/A | 98.9% |
| Dec 2023 | N/A | N/A | 72.4% |
| Sep 2023 | N/A | N/A | 31.9% |
| Jun 2023 | N/A | N/A | 45.7% |
| Mar 2023 | N/A | N/A | 31.6% |
| Dec 2022 | N/A | N/A | -27.6% |
ACAD's PEG ratio today comes in under the 3, 5 and 10-year averages.
Acadia Pharmaceuticals's PEG of 0.12 is lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.54, Acadia Pharmaceuticals's PEG is 78% lower.
ACAD carries a PEG ratio lower than that of peer stocks LLY and BMY.
Based on Oct 13, 2026 data, ACAD shows a PEG ratio of 0.12.
ACAD shows a 3-year average PEG ratio of 0.17.
ACAD shows a 5-year average PEG ratio of 0.17.
ACAD's PEG ratio topped out at 0.72 during the Jun 2024 quarter - the highest in three years.
ACAD currently has a PEG ratio 29% below its 3-year average.
The 0.12 PEG ratio for ACAD reflects robust earnings growth outpacing the current valuation.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Oct 13, 2026, Acadia Pharmaceuticals carries a PE ratio of 8.28. Earnings grew at 67.9% over the TTM period ending Jun 2026. Applying the formula, this yields a PEG ratio of 0.12. PEG RATIO(0.12) = PE RATIO(8.28) / EPS GROWTH(67.9%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.